How did compounding pharmacies need to adapt after the GLP-1 shortage ended?
Answered at 13:02 in Peptides, Telemedicine, Pharmacy & Compliance: The Future of Peptide Healthcare · B2B Vault: The Biz To Biz Podcast
How did compounding pharmacies need to adapt after the GLP-1 shortage ended?
When the FDA announced the end of its GLP-1 shortage declaration, it set a specific legal deadline for compounding pharmacies to cease all GLP-1 operations. LegitScript verified that 100 percent of merchants affected reached full compliance by the mandated timeframe, successfully exiting this temporary business line across the board.
The FDA Deadline and Merchant Coordination
The FDA's closure of the shortage window created an immediate compliance requirement rather than a gradual transition. Merchants received a formal deadline and had no discretion to continue compounding GLP-1 medications beyond that date. This regulatory action reflected the temporary nature of the shortage exemption that had allowed compounding pharmacies to operate in this space in the first place.
LegitScript's role was to ensure that merchants who had been selling GLP-1 products under the compounding window understood the requirement and executed their exit strategy on schedule. As discussed in the episode, the certification body reached out directly to affected merchants to confirm their compliance plans before the deadline arrived.
How Full Compliance Was Achieved
Proactive outreach and verification were key to ensuring no merchant inadvertently remained in violation after the FDA deadline. LegitScript contacted merchants across its network to document their intention to cease GLP-1 compounding operations and tracked their adherence to the announced timeline.
Full answer and detailsRead the whole answer, key facts and every other question from this episode
In short
When the FDA announced the end of its GLP-1 shortage declaration, it set a specific legal deadline for compounding pharmacies to cease all GLP-1 operations.
Allen Kopelman · Peptides, Telemedicine, Pharmacy & Compliance: The Future of Peptide Healthcare · B2B Vault: The Biz To Biz Podcast · answer at 13:02
Key takeaways
- LegitScript verified that 100 percent of merchants affected reached full compliance by the mandated timeframe, successfully exiting this temporary business line across the board.
- The FDA's closure of the shortage window created an immediate compliance requirement rather than a gradual transition.
- LegitScript's role was to ensure that merchants who had been selling GLP-1 products under the compounding window understood the requirement and executed their exit strategy on schedule.
- Proactive outreach and verification were key to ensuring no merchant inadvertently remained in violation after the FDA deadline.
The full answer · about 1 min
When the FDA announced the end of its GLP-1 shortage declaration, it set a specific legal deadline for compounding pharmacies to cease all GLP-1 operations. LegitScript verified that 100 percent of merchants affected reached full compliance by the mandated timeframe, successfully exiting this temporary business line across the board.
The FDA Deadline and Merchant Coordination
The FDA's closure of the shortage window created an immediate compliance requirement rather than a gradual transition. Merchants received a formal deadline and had no discretion to continue compounding GLP-1 medications beyond that date. This regulatory action reflected the temporary nature of the shortage exemption that had allowed compounding pharmacies to operate in this space in the first place.
LegitScript's role was to ensure that merchants who had been selling GLP-1 products under the compounding window understood the requirement and executed their exit strategy on schedule. As discussed in the episode, the certification body reached out directly to affected merchants to confirm their compliance plans before the deadline arrived.
How Full Compliance Was Achieved
Proactive outreach and verification were key to ensuring no merchant inadvertently remained in violation after the FDA deadline. LegitScript contacted merchants across its network to document their intention to cease GLP-1 compounding operations and tracked their adherence to the announced timeline.
More answers from this episode
- 5:29Why do payment processors and advertising platforms require LegitScript certification?
- 8:52How does LegitScript monitor merchants after certification?
- 15:56What enforcement actions have occurred against research-only peptide sellers?
- 18:05How does LegitScript treat websites that claim products are research-only while marketing them for human consumption?
- 24:05What documentation is required from a merchant applying for LegitScript certification?